Given the risk of complications (e.g., cirrhosis or hepatocellular carcinoma) in infants and young children who are infected with the HBV, as well as the benefits of vaccination and postexposure prophylaxis, the prevention and treatment of hepatitis B are considered cost-effective.
Hepatitis B cost-effectiveness of therapy
Hepatitis C cost-effectiveness of therapy
Hepatitis D cost-effectiveness of therapy
Hepatitis E cost-effectiveness of therapy
Hepatitis survival guide
Hepatitis E primary prevention
Hepatitis E future or investigational therapies
Hepatitis B diagnostic criteria